Therapeutic method and compositions for the treatment of juvenile diabetes mellitus
OwnerClaudio Cavazzainventor
Life of this patent
Estimating the term…
Abstract
The oral or parenteral administration of L-carnitine or certain acyl L-carnitines, typically propionyl L-carnitine, or the pharmacologically acceptable salts thereof, permits a considerable reduction (from 20 to approximately 50%) of the daily dose of insulin required by patients having juvenile diabetes mellitus to restore normal blood glucose levels. Moreover, L-carnitine and such acyl carnitines actively inhibit ketoacidosis, thus avoiding the risk of ketoacidosic coma in such patients.
Claims4
A sterile injectable pharmaceutical composition comprising:
- (a) insulin in a concentration of from about 20 to about 30 U/ml of composition;
- (b) at least one member selected from the group consisting of L-carnitine and the acetyl, propionyl, butyryl or hydroxybutyryl ester of L-carnitine in a concentration providing from about 0.2 to about 1 g/ml of composition;
- and
- (c) a pharmaceutically acceptable and injectable liquid carrier.
In the method of treating a human having juvenile diabetes mellitus with insulin, the improvement which comprises the administration to the human of a quantity of at least one member selected from the group consisting of L-carnitine and the acetyl, propionyl, butyryl and hydroxybutyryl ester thereof, at least sufficient to permit a significant reduction in the dosage of insulin otherwise required to maintain said human.
Dependencies are inferred from the claim text.